Lou Gehrig's stem cell study makes promising advance

Investigators led by Eva Feldman, a neurologist at the University of Michigan, have been given the green light to take another step forward in a small but very closely watched clinical trial of a new stem cell treatment for Lou Gehrig's disease. After successfully injecting stem cells into the lower spines of 12 patients with ALS, with no significant safety issues raising a red flag, the FDA has given the go-ahead on injections for the upper spine in a select group of six patients, Neuralstem ($CUR) announced. While not powered to provide solid efficacy data, on an anecdotal basis the therapy has provided some additional proof of concept. Story

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.